135 related articles for article (PubMed ID: 17013817)
1. Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab.
Cheung WW; Tse E; Leung AY; Yuen KY; Kwong YL
Am J Hematol; 2007 Feb; 82(2):108-11. PubMed ID: 17013817
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.
Laurenti L; Piccioni P; Cattani P; Cingolani A; Efremov D; Chiusolo P; Tarnani M; Fadda G; Sica S; Leone G
Haematologica; 2004 Oct; 89(10):1248-52. PubMed ID: 15477211
[TBL] [Abstract][Full Text] [Related]
3. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
O'Brien SM; Keating MJ; Mocarski ES
Clin Lymphoma Myeloma; 2006 Sep; 7(2):125-30. PubMed ID: 17026823
[TBL] [Abstract][Full Text] [Related]
4. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia.
Scheinberg P; Fischer SH; Li L; Nunez O; Wu CO; Sloand EM; Cohen JI; Young NS; John Barrett A
Blood; 2007 Apr; 109(8):3219-24. PubMed ID: 17148582
[TBL] [Abstract][Full Text] [Related]
5. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT
Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation.
Ng AP; Worth L; Chen L; Seymour JF; Prince HM; Slavin M; Thursky K
Haematologica; 2005 Dec; 90(12):1672-9. PubMed ID: 16330442
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab.
Lamba R; Carrum G; Myers GD; Bollard CM; Krance RA; Heslop HE; Brenner MK; Popat U
Bone Marrow Transplant; 2005 Nov; 36(9):797-802. PubMed ID: 16151431
[TBL] [Abstract][Full Text] [Related]
8. Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies.
Borthakur G; Lin E; Faderl S; Ferrajoli A; Wierda W; Giles F; Browning ML; Kantarjian H; Keating M; O'Brien S
Cancer; 2007 Dec; 110(11):2478-83. PubMed ID: 17960607
[TBL] [Abstract][Full Text] [Related]
9. Limited predictive value of real-time quantitative PCR cytomegalovirus monitoring in the blood. Fatal CMV pneumonia in an autologous stem cell transplant recipient previously treated with alemtuzumab.
Halaburda K; Nasiłowska-Adamska B; Grabarczyk P; Szczepiński A; Szpila T; Warzocha K; Mariańska B
Ann Transplant; 2007; 12(2):37-40. PubMed ID: 18173065
[TBL] [Abstract][Full Text] [Related]
10. Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab.
Vallejo C; Ríos E; de la Serna J; Jarque I; Ferrá C; Sánchez-Godoy P; Solano C; de la Cámara R; Rosell AI; Varela R; García MD; González-Barca E; López J; Pérez E; Ferrer S; Casado LF; Vázquez L; Villalón L; García-Marco JA
Expert Rev Hematol; 2011 Feb; 4(1):9-16. PubMed ID: 21322774
[TBL] [Abstract][Full Text] [Related]
11. Prospective cytomegalovirus monitoring during first-line chemotherapy in patients with acute myeloid leukemia.
Capria S; Gentile G; Capobianchi A; Cardarelli L; Gianfelici V; Trisolini SM; Foà R; Martino P; Meloni G
J Med Virol; 2010 Jul; 82(7):1201-7. PubMed ID: 20513085
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M
Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous alemtuzumab for Sézary Syndrome in the very elderly.
Alinari L; Geskin L; Grady T; Baiocchi RA; Bechtel MA; Porcu P
Leuk Res; 2008 Aug; 32(8):1299-303. PubMed ID: 18096224
[TBL] [Abstract][Full Text] [Related]
14. High incidence of cytomegalovirus, human herpesvirus-6, and Epstein-Barr virus reactivation in patients receiving cytotoxic chemotherapy for adult T cell leukemia.
Ogata M; Satou T; Kawano R; Yoshikawa T; Ikewaki J; Kohno K; Ando T; Miyazaki Y; Ohtsuka E; Saburi Y; Kikuchi H; Saikawa T; Kadota J
J Med Virol; 2011 Apr; 83(4):702-9. PubMed ID: 21328386
[TBL] [Abstract][Full Text] [Related]
15. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
16. Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic leukaemia.
Anoop P; Wotherspoon A; Matutes E
Br J Haematol; 2010 Feb; 148(3):484-6. PubMed ID: 19874308
[No Abstract] [Full Text] [Related]
17. Paraproteinaemia after allo-SCT, association with alemtuzumab-based conditioning and CMV reactivation.
Medd P; Littlewood S; Danby R; Malladi R; Clifford R; Wareham D; Jeffery K; Ferry B; Roberts D; Peniket A; Littlewood T
Bone Marrow Transplant; 2011 Jul; 46(7):993-9. PubMed ID: 20956951
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus retinitis after hematopoietic stem cell transplantation with alemtuzumab.
Song WK; Min YH; Kim YR; Lee SC
Ophthalmology; 2008 Oct; 115(10):1766-70. PubMed ID: 18562004
[TBL] [Abstract][Full Text] [Related]
19. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation.
Mori T; Okamoto S; Matsuoka S; Yajima T; Wakui M; Watanabe R; Ishida A; Iwao Y; Mukai M; Hibi T; Ikeda Y
Bone Marrow Transplant; 2000 Apr; 25(7):765-9. PubMed ID: 10745263
[TBL] [Abstract][Full Text] [Related]
20. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
Delgado J; Pillai S; Benjamin R; Caballero D; Martino R; Nathwani A; Lovell R; Thomson K; Perez-Simon JA; Sureda A; Kottaridis P; Vazquez L; Peggs K; Sierra J; Milligan D; Mackinnon S
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1288-97. PubMed ID: 18940684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]